Cargando…

Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications

BACKGROUND: Besides anti-citrullinated protein antibodies (ACPA), rheumatoid arthritis patients (RA) often display autoantibody reactivities against other post-translationally modified (PTM) proteins, more specifically carbamylated and acetylated proteins. Immunizing mice with one particular PTM res...

Descripción completa

Detalles Bibliográficos
Autores principales: Volkov, M., Kampstra, A. S. B., van Schie, K. A., Kawakami, A., Tamai, M., Kawashiri, S., Maeda, T., Huizinga, T. W. J., Toes, R. E. M., van der Woude, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653599/
https://www.ncbi.nlm.nih.gov/pubmed/34876234
http://dx.doi.org/10.1186/s13075-021-02687-5
_version_ 1784611697874436096
author Volkov, M.
Kampstra, A. S. B.
van Schie, K. A.
Kawakami, A.
Tamai, M.
Kawashiri, S.
Maeda, T.
Huizinga, T. W. J.
Toes, R. E. M.
van der Woude, D.
author_facet Volkov, M.
Kampstra, A. S. B.
van Schie, K. A.
Kawakami, A.
Tamai, M.
Kawashiri, S.
Maeda, T.
Huizinga, T. W. J.
Toes, R. E. M.
van der Woude, D.
author_sort Volkov, M.
collection PubMed
description BACKGROUND: Besides anti-citrullinated protein antibodies (ACPA), rheumatoid arthritis patients (RA) often display autoantibody reactivities against other post-translationally modified (PTM) proteins, more specifically carbamylated and acetylated proteins. Immunizing mice with one particular PTM results in an anti-modified protein antibody (AMPA) response recognizing different PTM-antigens. Furthermore, human AMPA, isolated based on their reactivity to one PTM, cross-react with other PTMs. However, it is unclear whether the AMPA-reactivity profile is “fixed” in time or whether consecutive exposure to different PTMs can shape the evolving AMPA response towards a particular PTM. METHODS: Longitudinally collected serum samples of 8 human individuals at risk of RA and 5 with early RA were tested with ELISA, and titers were analyzed to investigate the evolution of the AMPA responses over time. Mice (13 per immunization group in total) were immunized with acetylated (or carbamylated) protein (ovalbumin) twice or cross-immunized with an acetylated and then a carbamylated protein (or vice versa) and their serum was analyzed for AMPA responses. RESULTS: Human data illustrated dynamic changes in AMPA-reactivity profiles in both individuals at risk of RA and in early RA patients. Mice immunized with either solely acetylated or carbamylated ovalbumin (AcOVA or CaOVA) developed reactivity against both acetylated and carbamylated antigens. Irrespective of the PTM-antigen used for the first immunization, a booster immunization with an antigen bearing the other PTM resulted in increased titers to the second/booster PTM. Furthermore, cross-immunization skewed the overall AMPA-response profile towards a relatively higher reactivity against the “booster” PTM. CONCLUSIONS: The relationship between different reactivities within the AMPA response is dynamic. The initial exposure to a PTM-antigen induces cross-reactive responses that can be boosted by an antigen bearing this or other PTMs, indicating the formation of cross-reactive immunological memory. Upon subsequent exposure to an antigen bearing another type of PTM, the overall reactivity pattern can be skewed towards better recognition of the later encountered PTM. These data might explain temporal differences in the AMPA-response profile and point to the possibility that the PTM responsible for the initiation of the AMPA response may differ from the PTM predominantly recognized later in time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02687-5.
format Online
Article
Text
id pubmed-8653599
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86535992021-12-08 Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications Volkov, M. Kampstra, A. S. B. van Schie, K. A. Kawakami, A. Tamai, M. Kawashiri, S. Maeda, T. Huizinga, T. W. J. Toes, R. E. M. van der Woude, D. Arthritis Res Ther Research Article BACKGROUND: Besides anti-citrullinated protein antibodies (ACPA), rheumatoid arthritis patients (RA) often display autoantibody reactivities against other post-translationally modified (PTM) proteins, more specifically carbamylated and acetylated proteins. Immunizing mice with one particular PTM results in an anti-modified protein antibody (AMPA) response recognizing different PTM-antigens. Furthermore, human AMPA, isolated based on their reactivity to one PTM, cross-react with other PTMs. However, it is unclear whether the AMPA-reactivity profile is “fixed” in time or whether consecutive exposure to different PTMs can shape the evolving AMPA response towards a particular PTM. METHODS: Longitudinally collected serum samples of 8 human individuals at risk of RA and 5 with early RA were tested with ELISA, and titers were analyzed to investigate the evolution of the AMPA responses over time. Mice (13 per immunization group in total) were immunized with acetylated (or carbamylated) protein (ovalbumin) twice or cross-immunized with an acetylated and then a carbamylated protein (or vice versa) and their serum was analyzed for AMPA responses. RESULTS: Human data illustrated dynamic changes in AMPA-reactivity profiles in both individuals at risk of RA and in early RA patients. Mice immunized with either solely acetylated or carbamylated ovalbumin (AcOVA or CaOVA) developed reactivity against both acetylated and carbamylated antigens. Irrespective of the PTM-antigen used for the first immunization, a booster immunization with an antigen bearing the other PTM resulted in increased titers to the second/booster PTM. Furthermore, cross-immunization skewed the overall AMPA-response profile towards a relatively higher reactivity against the “booster” PTM. CONCLUSIONS: The relationship between different reactivities within the AMPA response is dynamic. The initial exposure to a PTM-antigen induces cross-reactive responses that can be boosted by an antigen bearing this or other PTMs, indicating the formation of cross-reactive immunological memory. Upon subsequent exposure to an antigen bearing another type of PTM, the overall reactivity pattern can be skewed towards better recognition of the later encountered PTM. These data might explain temporal differences in the AMPA-response profile and point to the possibility that the PTM responsible for the initiation of the AMPA response may differ from the PTM predominantly recognized later in time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02687-5. BioMed Central 2021-12-08 2021 /pmc/articles/PMC8653599/ /pubmed/34876234 http://dx.doi.org/10.1186/s13075-021-02687-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Volkov, M.
Kampstra, A. S. B.
van Schie, K. A.
Kawakami, A.
Tamai, M.
Kawashiri, S.
Maeda, T.
Huizinga, T. W. J.
Toes, R. E. M.
van der Woude, D.
Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
title Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
title_full Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
title_fullStr Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
title_full_unstemmed Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
title_short Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
title_sort evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653599/
https://www.ncbi.nlm.nih.gov/pubmed/34876234
http://dx.doi.org/10.1186/s13075-021-02687-5
work_keys_str_mv AT volkovm evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT kampstraasb evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT vanschieka evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT kawakamia evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT tamaim evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT kawashiris evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT maedat evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT huizingatwj evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT toesrem evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications
AT vanderwouded evolutionofantimodifiedproteinantibodyresponsescanbedrivenbyconsecutiveexposuretodifferentposttranslationalmodifications